Deruxtecan
CAS No. 1599440-13-7
Deruxtecan ( —— )
产品货号. M26662 CAS No. 1599440-13-7
Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥3062 | 有现货 |
|
10MG | ¥4026 | 有现货 |
|
25MG | ¥6116 | 有现货 |
|
100MG | 获取报价 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Deruxtecan
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
-
产品描述Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.(In Vitro):Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体E3 Ligase
-
研究领域——
-
适应症——
化学信息
-
CAS Number1599440-13-7
-
分子量1034.1
-
分子式C52H56FN9O13
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](NC(=O)COCNC(=O)CNC(=O)[C@H](Cc6ccccc6)NC(=O)CNC(=O)CNC(=O)CCCCCN6C(=O)C=CC6=O)c(c3Cn1c2=O)c45
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Boscaro C, et al. Non-genomic mechanisms in the estrogen regulation of glycolytic protein levels in endothelial cells. FASEB J. 2020 Sep;34(9):12768-12784.
产品手册
关联产品
-
trans-Methylisoeugen...
Trans-Methylisoeugenol is a compound with insecticidal activity isolated from Acorus calamus L. It is a natural food flavor.
-
1-(3,5-dimethoxy)phe...
1-(3',5'-dimethoxy)phenyl-2-[4''-O-β-D-glucopyranosyl (6→1)-O-α-L-rhamnopyranosyl]phenylethane showed cytotoxic activities to Hela and hep2 cell lines.
-
Ginsenoside Ra1
Ginsenoside Ra1 is a component from ginseng. Ginsenoside Ra1 shows significant inhibitory effects on protein tyrosine kinase (PTK) activation induced by hypoxia/reoxygenation (H/R).